ChiCTR2000035232 版本V1.0 版本创建时间2020/08/04 18:51:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000035232 

最近更新日期:

Date of Last Refreshed on:

2020-08-04 18:51:47 

注册时间:

Date of Registration:

1990-01-01 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

富氢水干预吸烟人群患外周动脉疾病风险的临床效果研究

Public title:

The effect of hydrogen-rich water on the risk of peripheral arterial disease in smokers: a clinical study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

富氢水干预吸烟人群患外周动脉疾病风险的临床效果研究

Scientific title:

The effect of hydrogen-rich water on the risk of peripheral arterial disease in smokers: a clinical study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谷茜茜 

研究负责人:

秦树存 

Applicant:

Qianqian Gu 

Study leader:

Shucun Qin 

申请注册联系人电话:

Applicant telephone:

+86 15854856226

研究负责人电话:

Study leader's
telephone:

+86 0538 6222986

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

guqianecho@163.com

研究负责人电子邮件:

Study leader's E-mail:

scqin@sdfmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省泰安市迎胜东路2号

研究负责人通讯地址:

山东省泰安市迎胜东路2号

Applicant address:

2 Yingsheng Road East,Taian, Shandong

Study leader's address:

2 Yingsheng Road East,Taian, Shandong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东第一医科大学(山东省医学科学院)

Applicant's institution:

Shandong First Medical University & Shangdong Academy of Medical Sciences

研究负责人所在单位:

山东第一医科大学(山东省医学科学院)

Affiliation of the Leader:

Shandong First Medical University & Shangdong Academy of Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019121

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

泰山医学院伦理委员会

Name of the ethic committee:

Ethics Committee of Taishan Medical College

伦理委员会批准日期:

Date of approved by ethic committee:

2019-11-05 00:00:00

伦理委员会联系人:

尹瑞法

Contact Name of the ethic committee:

Ruifa Yin

伦理委员会联系地址:

山东省泰安市长城路619号

Contact Address of the ethic committee:

619 ChangCheng Road, Taian, Shandong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东第一医科大学(山东省医学科学院)

Primary sponsor:

Shandong First Medical University &Shandong Academy of Medical Sciences

研究实施负责(组长)单位地址:

山东省泰安市迎胜东路2号

Primary sponsor's address:

2 Yingsheng Road East, Taian, Shandong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

泰安

Country:

China

Province:

Shandong

City:

Taian

单位(医院):

山东第一医科大学(山东省医学科学院)

具体地址:

迎胜东路2号

Institution
hospital:

Shandong First Medical University & Shangdong Academy of Medical Sciences

Address:

2 Yingsheng Road East

经费或物资来源:

国家自然科学基金(81770855);山东省泰山学者岗专项基金(ts201511057);山东第一医科大学学术提升计划(2019QL010)

Source(s) of funding:

National Natural Science Foundation of China (81770855); Shandong Taishan Scholars Fund (ts201511057); Shandong First Medical University Academic Promotion Program (2019QL010)

研究疾病:

外周动脉疾病  

Target disease:

Peripheral arterial disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

II期临床试验 

Study phase:

2

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

(1)明确富氢水对吸烟人群外周动脉疾病的血脂、氧化应激、炎症水平、ABI、PWV、睡眠质量、焦虑抑郁及健康行为方式的临床效果,探索外周动脉疾病新的治疗方法。 (2)为富氢水可以减少吸烟对外周动脉损伤以及减少负面情绪和提高睡眠质量、改善健康行为方式提供临床依据。 (3)开展细胞实验,进一步验证富氢水对吸烟人群外周动脉疾病患者内皮细胞的保护作用及作用机制。  

Objectives of Study:

(1) To clarify the clinical effects of hydrogen-rich water on blood lipids, oxidative stress, inflammation levels, ABI, PWV, sleep quality, anxiety, depression, and healthy behaviors in peripheral arterial disease in smokers, and to explore new treatments for peripheral arterial disease. (2) Provide a clinical basis for hydrogen-rich water to reduce smoking and damage to peripheral arteries, reduce negative emotions, improve sleep quality, and improve healthy behaviors. (3) Carry out cell experiments to further verify the protective effect and mechanism of hydrogen-rich water on endothelial cells in patients with peripheral arterial disease in smokers.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)目前吸烟者或者戒烟10年以内;
2)年龄≥40周岁;
3) 有症状的PAD患者,包括间歇性跛行、静息痛、腿部疼痛等;或者无症状PAD患者ABI<1.0;或吸烟指数(吸烟强度x吸烟持续时间)≥200;
4)有或无糖尿病、高血压、高血脂危险因素;
5)能独立或在研究者帮助下完成问卷填写;
6)签署知情同意书。

Inclusion criteria

1) Current smoker or quit smoking within 10 years;
2) Age ≥40 years;
3) Patients with symptomatic PAD, including intermittent claudication, resting pain, leg pain, etc .; or ABI <1.0 in asymptomatic PAD patients; or smoking index (smoking intensity x smoking duration) ≥200
4) With or without risk factors for diabetes, hypertension, and hyperlipidemia;
5) Can complete the questionnaire independently or with the help of researchers;
6) Sign the informed consent.

排除标准:

1)由于血管不可压缩无法获得ABI值的患者;
2)具有严重的糖尿病患者且控制不良和难治性高血压患者;
3) 有严重的肝肾疾病和癌症患者;
4) 严重的肢体缺血,截肢,或者最近六个月血管重建术;
5)意识不清或不合作,以及伴有认识精神障碍者;

Exclusion criteria:

1) Patients who cannot obtain ABI value due to incompressible blood vessels;
2) Patients with severe diabetes and poorly controlled and refractory hypertension;
3) Patients with severe liver and kidney disease and cancer;
4) Severe limb ischemia, amputation, or revascularization in the last six months;
5) People who are unconscious or uncooperative, and who are accompanied by cognitive disorders;

研究实施时间:

Study execute time:

From 2019-11-18 00:00:00 To 2020-01-18 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-10-01 00:00:00 To 2019-11-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

30

Group:

Trial group

Sample size:

干预措施:

饮用富氢水

干预措施代码:

Intervention:

Drinking Hydrogen water

Intervention code:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

饮用普通水

干预措施代码:

Intervention:

Drinking Placebo

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

粥店社区 

单位级别:

无 

Institution
hospital:

Zhoudian community

Level of the institution:

N/A

测量指标:

Outcomes:

指标中文名:

踝臂指数

指标类型:

主要指标

Outcome:

ankle brachial index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脉搏波传导速度

指标类型:

主要指标

Outcome:

PWV

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

丙二醛

指标类型:

主要指标

Outcome:

MDA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超氧化物歧化酶

指标类型:

主要指标

Outcome:

SOD

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞介素6

指标类型:

主要指标

Outcome:

IL-6

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子-α

指标类型:

主要指标

Outcome:

TNF-α

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总胆固醇

指标类型:

次要指标

Outcome:

TC

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甘油三脂

指标类型:

次要指标

Outcome:

TG

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高密度脂蛋白

指标类型:

次要指标

Outcome:

HDL

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白

指标类型:

次要指标

Outcome:

LDL

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

睡眠质量指数

指标类型:

次要指标

Outcome:

Pittsburgh sleep quality index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑

指标类型:

次要指标

Outcome:

anxiety

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁

指标类型:

次要指标

Outcome:

depressed

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

主要指标

Outcome:

CRP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

研究人员用Excle表中随机随机数字表法进行随机抽样

Randomization Procedure (please state who generates the random number sequence and by what method):

Researchers use random random number table method in Excel table for random sampling

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后原始数据在本注册中心公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Data sharing will be able to access in ChiCTR after the trial finished

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有数据均采用CRF表记录,采用excel表格进行管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data was recorded by CRF chart and managed by excel.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-08-04 18:51:48